Amyotrophic lateral sclerosis (ALS), sometimes called Lou Gehrig's disease, is a rapidly progressive, invariably fatal neurological disease that attacks the body's nerve cells (or "neurons"), which are responsible for controlling voluntary muscle movement - that includes moving the arms, legs, face and more. The disease belongs to a group of disorders known as motor neuron diseases, which are characterized by the gradual degeneration and death of motor neurons.
When motor neurons degenerate or die, muscles no longer receive signals from the brain that they need to move. Unable to function, the muscles gradually weaken, atrophy and experience very subtle twitches (called "fasciculations"). Eventually, the ability of the brain to start and control voluntary movement is lost. When muscles in the diaphragm and chest wall fail, people lose the ability to breathe without ventilatory support. Most people with ALS die from respiratory failure, usually within 3 to 5 years from the onset of symptoms. However, about 10 percent of those with ALS survive for 10 or more years.
Although the disease usually does not impair a person's mind or intelligence, several recent studies suggest that some people with ALS may have depression or alterations in cognitive functions involving decision-making and memory. Patients usually maintain control of eye muscles and bladder and bowel functions, and ALS does not affect a person's ability to see, smell, taste, hear, or recognize touch.
ALS is classified as a rare disease, but is the most common motor neuron disease, which affects people of all races and ethnicities equally.
In much of the world, rates of ALS are unknown. In Europe, the disease affects about 2.2 people per 100,000 per year. In the United States, more than 5,600 are diagnosed every year, and up to 30,000 Americans are currently affected. ALS is responsible for two deaths per 100,000 people per year.
In 90 to 95 percent of all ALS cases, the disease occurs apparently at random with no clearly associated risk factors. Individuals with this sporadic form of the disease have no family history of ALS, and their family members are not considered to be at increased risk for developing it. About five to ten percent of all ALS cases are inherited. The familial form of ALS usually results from a pattern of inheritance that requires only one parent to carry the gene responsible for the disease. Mutations in more than a dozen genes have been found to cause familial ALS.
The onset of ALS may be so subtle that the symptoms are overlooked. The earliest symptoms may include fasciculations, cramps, tight and stiff muscles, muscle weakness affecting an arm or a leg, slurred and nasal speech, or difficulty chewing or swallowing. These general complaints then develop into more obvious weakness or atrophy that may cause a physician to suspect ALS.
Many individuals first see the effects of the disease in a hand or arm as they experience difficulty with simple tasks requiring manual dexterity such as buttoning a shirt, writing, or turning a key in a lock. In other cases, symptoms initially affect one of the legs, and people experience awkwardness when walking or running or they notice that they are tripping or stumbling more often.
Regardless of the part of the body first affected by the disease, muscle weakness and atrophy spread to other parts of the body as the disease progresses. Individuals may develop problems with moving, swallowing (dysphagia), and speaking or forming words (dysarthria), as well as muscle spasticity, exaggerated reflexes, muscle weakness and atrophy, muscle cramps and fasciculations.
Although the sequence of emerging symptoms and the rate of disease progression vary from person to person, eventually individuals will not be able to stand or walk, get in or out of bed on their own, or use their hands and arms. Difficulty swallowing and chewing impair the person's ability to eat normally and increase the risk of choking. Maintaining weight will then become a problem. Because cognitive abilities are relatively intact, people are aware of their progressive loss of function and may become anxious and depressed.
A small percentage of individuals may experience problems with memory or decision-making, and there is growing evidence that some may even develop a form of dementia over time. Health care professionals need to explain the course of the disease and describe available treatment options so that people can make informed decisions in advance. In later stages of the disease, individuals have difficulty breathing as the muscles of the respiratory system weaken. They eventually lose the ability to breathe on their own and must depend on ventilatory support for survival. Affected individuals also face an increased risk of pneumonia during later stages of ALS.
To be diagnosed with ALS, people must have signs and symptoms of both upper and lower motor neuron damage that cannot be attributed to other causes. No single test can provide a definitive diagnosis of ALS; instead, the diagnosis of ALS is primarily based on the symptoms and signs the physician observes in the patient and a series of tests to rule out other diseases. Physicians obtain the individual's full medical history and usually conduct a neurologic examination at regular intervals to assess whether symptoms such as muscle weakness, atrophy of muscles, hyperreflexia and spasticity are getting progressively worse.
Since ALS symptoms in the early stages of the disease can be similar to those of a wide variety of other, more treatable diseases or disorders, appropriate tests must be conducted to exclude the possibility of other conditions. One of these tests is electromyography (EMG), a special recording technique that detects electrical activity in muscles. Certain EMG findings can support the diagnosis of ALS. Another common test is a nerve conduction study (NCS), which measures electrical energy by assessing the nerve's ability to send a signal. Specific abnormalities in the NCS and EMG may suggest, for example, that the individual has a form of peripheral neuropathy (damage to peripheral nerves) or myopathy (muscle disease) rather than ALS.
The physician may order magnetic resonance imaging (MRI), a noninvasive procedure that uses a magnetic field and radio waves to take detailed images of the brain and spinal cord. Standard MRI scans are normal in people with ALS. However, they can reveal evidence of other problems that may be causing the symptoms, such as a spinal cord tumor, a herniated disk in the neck that compresses the spinal cord, syringomyelia (a cyst in the spinal cord), or cervical spondylosis (abnormal wear affecting the spine in the neck).
Based on the person's symptoms and findings from the examination and from these tests, the physician may order tests on blood and urine samples to eliminate the possibility of other diseases as well as routine laboratory tests. In some cases, for example, if a physician suspects that the individual may have a myopathy rather than ALS, a muscle biopsy may be performed.
Infectious diseases such as human immunodeficiency virus (HIV), human T-cell leukemia virus (HTLV), polio, West Nile virus, and Lyme disease can cause ALS-like symptoms in some cases. Neurological disorders such as multiple sclerosis, post-polio syndrome, multifocal motor neuropathy, and spinal muscular atrophy also can mimic certain facets of the disease and should be considered by physicians attempting to make a diagnosis. Fasciculations, the fine rippling movements in the muscle, and muscle cramps also occur in benign conditions.
Because of the prognosis carried by this diagnosis and the variety of diseases or disorders that can resemble ALS in the early stages of the disease, individuals may wish to obtain a second neurological opinion.
The cause of ALS is not known, and scientists do not yet know why ALS strikes some people and not others.
An important step toward answering this question was made in 1993 when scientists discovered that mutations in the gene that produces the SOD1 enzyme were associated with some cases of familial ALS. Although it is still not clear how mutations in the SOD1 gene lead to motor neuron degeneration, there is increasing evidence that mutant SOD1 protein can become toxic.
Since then, over a dozen additional genetic mutations have been identified, many through research supported by the National Institute of Neurological Disorders and Stroke (NINDS), and each of these gene discoveries has provided new insights into possible mechanisms of ALS. For example, the discovery of certain genetic mutations involved in ALS suggests that changes in the processing of RNA molecules (involved with functions including gene regulation and activity) may lead to ALS-related motor neuron degeneration. Other gene mutations implicate defects in protein recycling. And still others point to possible defects in the structure and shape of motor neurons, as well as increased susceptibility to environmental toxins. Overall, it is becoming increasingly clear that a number of cellular defects can lead to motor neuron degeneration in ALS.
Another research advance was made in 2011 when scientists found that a defect in the C9orf72 gene is not only present in a significant subset of ALS patients but also in some patients who suffer from a type of frontotemporal dementia (FTD). This observation provides evidence for genetic ties between these two neurodegenerative disorders. In fact, some researchers are proposing that ALS and some forms of FTD are related disorders with genetic, clinical, and pathological overlap.
In searching for the cause of ALS, researchers are also studying the role of environmental factors such as exposure to toxic or infectious agents, as well as physical trauma or behavioral and occupational factors. For example, studies of populations of military personnel who were deployed to the Gulf region during the 1991 war show that those veterans were more likely to develop ALS compared to military personnel who were not in the region.
Future research may show that many factors, including a genetic predisposition, are involved in the development of ALS.
No cure has yet been found for ALS. However, the Food and Drug Administration (FDA) approved the first drug treatment for the disease, called Riluzole (Rilutek), in 1995. Riluzole is believed to reduce damage to motor neurons by decreasing the release of glutamate. Clinical trials with ALS patients showed that Riluzole prolongs survival by several months, mainly in those with difficulty swallowing. The drug could also extend the time before an individual needs ventilation support. Riluzole does not reverse the damage already done to motor neurons, and persons taking the drug must be monitored for liver damage and other possible side effects. However, this first disease-specific therapy offers hope that new medications or combinations of drugs may one day be used to slow the progression of ALS.
Other treatments for ALS are designed to relieve symptoms and improve the quality of life for individuals with the disorder. This supportive care is best provided by multidisciplinary teams of health care professionals such as physicians; pharmacists; physical, occupational, and speech therapists; nutritionists; and social workers and home care and hospice nurses. Working with patients and caregivers, these teams can design an individualized plan of medical and physical therapy and provide special equipment aimed at keeping patients as mobile and comfortable as possible.
Physicians can prescribe medications to help reduce fatigue, ease muscle cramps, control spasticity, and reduce excess saliva and phlegm. Drugs also are available to help patients with pain, depression, sleep disturbances, and constipation. Pharmacists can give advice on the proper use of medications and monitor a patient's prescriptions to avoid risks of drug interactions.
Physical therapy and special equipment can enhance an individual's independence and safety throughout the course of ALS. Gentle, low-impact aerobic exercise such as walking, swimming, and stationary bicycling can strengthen unaffected muscles, improve cardiovascular health, and help patients fight fatigue and depression. Range of motion and stretching exercises can help prevent painful spasticity and shortening (contracture) of muscles. Physical therapists can recommend exercises that provide these benefits without overworking muscles. Occupational therapists can suggest devices such as ramps, braces, walkers, and wheelchairs that help individuals conserve energy and remain mobile.
People with ALS who have difficulty speaking may benefit from working with a speech therapist. These health professionals can teach individuals adaptive strategies such as techniques to help them speak louder and more clearly. As ALS progresses, speech therapists can help people develop ways for responding to yes-or-no questions with their eyes or by other nonverbal means and can recommend aids such as speech synthesizers and computer-based communication systems. These methods and devices help people communicate when they can no longer speak or produce vocal sounds.
Nutritional support is an important part of the care of people with ALS. Individuals and caregivers can learn from speech therapists and nutritionists how to plan and prepare numerous small meals throughout the day that provide enough calories, fiber, and fluid and how to avoid foods that are difficult to swallow. People may begin using suction devices to remove excess fluids or saliva and prevent choking. When individuals can no longer get enough nourishment from eating, doctors may advise inserting a feeding tube into the stomach. The use of a feeding tube also reduces the risk of choking and pneumonia that can result from inhaling liquids into the lungs. The tube is not painful and does not prevent individuals from eating food orally if they wish.
When the muscles that assist in breathing weaken, use of nocturnal ventilatory assistance (intermittent positive pressure ventilation [IPPV] or bilevel positive airway pressure [BIPAP]) may be used to aid breathing during sleep. Such devices artificially inflate the person's lungs from various external sources that are applied directly to the face or body. Individuals with ALS will have breathing tests on a regular basis to determine when to start non-invasive ventilation (NIV). When muscles are no longer able to maintain normal oxygen and carbon dioxide levels, these devices may be used full-time. The NeuRx Diaphragm Pacing System, which uses implanted electrodes and a battery pack to cause the diaphragm (breathing muscle) to contract, has been approved by the Food and Drug Administration to help certain individuals who have ALS and breathing problems an average benefit of up to 16 months before onset of severe respiratory failure.
Individuals may eventually consider forms of mechanical ventilation (respirators) in which a machine inflates and deflates the lungs. To be effective, this may require a tube that passes from the nose or mouth to the windpipe (trachea) and for long-term use, an operation such as a tracheostomy, in which a plastic breathing tube is inserted directly in the patient's windpipe through an opening in the neck. Patients and their families should consider several factors when deciding whether and when to use one of these options. Ventilation devices differ in their effect on the person's quality of life and in cost. Although ventilation support can ease problems with breathing and prolong survival, it does not affect the progression of ALS. People need to be fully informed about these considerations and the long-term effects of life without movement before they make decisions about ventilation support.
Social workers and home care and hospice nurses help patients, families, and caregivers with the medical, emotional, and financial challenges of coping with ALS, particularly during the final stages of the disease. Respiratory therapists can help caregivers with tasks such as operating and maintaining respirators, and home care nurses are available not only to provide medical care but also to teach caregivers about giving tube feedings and moving patients to avoid painful skin problems and contractures. Home hospice nurses work in consultation with physicians to ensure proper medication and pain control.
Scientists are seeking to understand the mechanisms that selectively trigger motor neurons to degenerate in ALS, and to find effective approaches to halt the processes leading to cell death. This work includes studies in animals to identify the molecular means by which ALS-causing gene mutations lead to the destruction of neurons. To this end, scientists have developed models of ALS in a variety of animal species, including fruit flies, zebrafish, and rodents. Initially, these genetically modified animal models focused on mutations in the SOD1 gene but more recently, models harboring other ALS-causing mutations also have been developed. Research in these models suggests that depending on the gene mutation, motor neuron death is caused by a variety of cellular defects, including in the processing of RNA molecules and recycling of proteins, as well as impaired energy metabolism, and hyperactivation of motor neurons. Increasing evidence also suggests that various types of glial support cells and inflammation cells of the nervous system play an important role in the disease.
Overall, the work in familial ALS is already leading to a greater understanding of the more common sporadic form of the disease. Because familial ALS is virtually indistinguishable from sporadic ALS clinically, some researchers believe that familial ALS genes may also be involved in sporadic ALS. For example, recent research has shown that the defect in the C9orf72 gene found in familial ALS is also present in a small percentage of sporadic ALS cases. Further, there is evidence that mutant SOD1 is present in spinal cord tissue in some sporadic cases of ALS.
Another active area of research is the development of innovative cell culture systems to serve as "patient-derived" model systems for ALS research. For example, scientists have developed ways of inducing skin cells from individuals with ALS into becoming pluripotent stem cells (cells that are capable of becoming all of the different cell types of the body). In the case of ALS, researchers have been able to convert pluripotent stem cells derived from skin into becoming motor neurons and other cell types that may be involved in the disease. NINDS is supporting research on the development of pluripotent cell lines for a number of neurodegenerative diseases, including ALS.
Scientists are also working to develop biomarkers for ALS that could serve as tools for diagnosis, as markers of disease progression, or could be correlated with therapeutic targets. Such biomarkers can be molecules derived from a bodily fluid (such as spinal fluid), an imaging assay of the brain or spinal cord, or an electrophysiological measure of nerve and muscle ability to process an electrical signal.
Potential therapies for ALS are being investigated in a range of animal models, especially in rodent models. But many research projects are surrounding patients' own cells as testing resources. The use of skin or blood samples to replicate the patient's specific form of ALS through induced pluripotent stem cells (also known as iPS cells) could potentially accelerate drug testing and trials and mark a significant change in all disease research. This work involves the testing of drug-like compounds, gene therapy approaches, antibodies and cell-based therapies. At any given time, a number of exploratory treatments are in clinical testing in ALS patients. Investigators are optimistic that these and other basic, translational, and clinical research studies will eventually lead to new and more effective treatments for ALS.
By Jeffrey D. Rothstein
Neurologist and professor at Johns Hopkins University and director of the University's Brain Science Institute, ALS clinic and Robert Packard Center for ALS Research.
Because ALS symptoms include fatigue, muscle weakness and muscle twitches, early on it can look like other very treatable illnesses. One that commonly comes up is Lyme disease, an infectious disease resulting from a tick bite. Unlike ALS, Lyme is usually treatable with antibiotics. Lyme disease does not cause ALS, and generally in a diagnostic workup, a neurologist can easily separate ALS from Lyme infections, either clinically or with testing.
This is a long-standing myth held by physicians and patients: that ALS patients' minds remain sharp as their bodies deteriorate. But newer studies show that about 20 to 30 percent of patients develop a mild cognitive impairment, while a very small number, about 5 to 10 percent, get severe dementia.
This idea comes from the observation that older people get degenerative diseases such as ALS, Alzheimer's and Parkinson's, and those who become the public faces of the disease are typically older. But the median age for the onset of ALS is only 54. Lou Gehrig was diagnosed in his mid-30s and passed away from ALS at age 38. The age range for developing ALS is large, from teenagers to as old as one can get.
We don't know if this is true for all sports. Some data suggest that football players are at higher risk to develop ALS, but more research needs to be done to see how widespread that risk is for other contact sports. There have been a number of prominent young athletes with ALS, starting with Gehrig. And Steve Gleason, formerly a defensive back with the New Orleans Saints, has wonderfully shown how patients can fight the disease, using various tools to help them communicate when their vocal muscles start to fail, while they await better therapies to stop or reverse the disease. There is incomplete research suggesting that a career in professional sports may increase a person's likelihood of getting ALS, possibly because of trauma to athletes' nervous systems. But most others who get the disease are relatively inactive. Some have thought that exercise makes ALS worse, but as best as neurologists can tell, muscle activity will not worsen the disease. In fact, an ongoing study at the Johns Hopkins ALS clinic is trying to determine if regular, simple exercise can slow the progression of ALS. For some patients, exercise can quickly make them very tired, but there is no good evidence that exercise speeds up the disease.
This idea stems from the fact that we have so few drugs that slow the progression of ALS. Only one FDA-approved drug exists for ALS - and it reins in the disease only modestly. Since then, there have been many clinical trials of medications designed to slow ALS, but all have failed, in part because of incomplete understanding of the disease. Despite such setbacks, there has been a significant increase in the number of pharmaceutical companies that are interested in ALS and have the right experience to carry out research and clinical trials. This rising interest over the past few years may reflect the exciting discoveries about ALS and the new tools to study it, one of the most important being stem cell patients. These cells may better reflect the disease and allow better drug development. ALS research is largely funded by the National Institutes of Health and many nonprofit organizations.
There are an incredible number of organizations that can offer support to people with ALS and their families. We've compiled a list of trusted advocacy and research organizations, clinics, support groups and more here.
We're always seeking out organizations, companies and individuals who are helping those living with ALS, and we will update this list as we discover new resources. If you would like to recommend a resource, please send us your submissions at firstname.lastname@example.org.
Communications needs for people living with ALS are as varied and unique as the people themselves. for people living with ALS can be broken down into two categories: low tech and high tech. Both are very important and need to be understood. It is imperative that a person be well versed with both categories.
The links below are meant to provide people with ALS and their caregivers a brief overview of the types of resources available to them, including low- and high-tech Augmentative and Alternative Communication (AAC) and commercial systems. The systems below do not include voice-banking options, however - we are working to develop a comprehensive list for this option, but please contact us with any questions you may have in the meantime.
American Speech (Language Hearing Association): http://www.asha.org/
Amy and pALS
(Designed by communication specialist Amy Roman, specifically for people living with ALS): http://amyandpals.com
Broadened Horizons: http://www.broadenedhorizons.com
RJ Cooper: http://rjcooper.com
Adaptive Switch Laboratories: http://www.asl-inc.com
FRS Solutions: http://www.frs-solutions.com
LC Technologies: http://www.eyegaze.com/eye-tracking-assistive-tech...
The assistive technology field is advancing day by day, and we believe that increasing the availability of these innovative technologies for people with ALS is a short-term initiative that can have a remarkable impact on quality of life. We'll do everything we can today to help patients and families living with ALS to lead more productive and purpose-filled lives.
ALS kills the brain's motor neurons. As these degenerate, the brain loses its ability to initiate and control muscle movement, and the body is slowly paralyzed. People with ALS - no matter their age or ability - have the right to affordable assistive information technologies and services that will allow them to participate in society as active citizens, even as their disease progresses.
Assistive technologies seamlessly integrate into daily life for use at home, in the workplace, in the classroom and in the community. They range from very low-cost, low-tech devices like reach-extenders or adapted bottle openers to high-tech, very expensive devices like powered wheelchairs, stair lifts and environmental controls that respond to voice, touch or eye-track commands.
We need to focus on creating more creative solutions for people with ALS so they can continue to live, learn, work and play without placing undue financial hardships and burdens on themselves and the people in their lives. Assistive technologies need to address just about any task an individual might want to perform, since people living with ALS will rely on them to maintain a productive, independent life.
Encourage translational faculty offices within universities to function as business incubators for inventors-turned-entrepreneurs. Current projects at Tulane University, Washington State University and Oregon State University have already resulted in assistive technology advancements.
Invent a technology-rights marketplace where investors can bid on the development of patented but undeveloped technologies. We call this "Venture Altruism."
Provide a funding pool or prized-based system to assist early research and development of new technologies that can be applied to ALS assistance. In return, entrepreneurs must provide beta-test access to patients.
Expand access to assistive technology and life-sustaining equipment to anyone who needs it through public policy creation and corporate and organizational alignment.
Create The National ALS Awareness Act to help shape a governance model to influence a structural war on ALS.
Support and align with the ALS Residence Initiative, which promotes the expansion of residences where people with ALS can live with the support of assistive technology and ALS-specific care.
Please support Answer ALS and help accelerate research and increase support for people living with ALS. Contributions to Answer ALS are tax deductible within the guidelines of state and federal law.